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ABSTRAK
Latar belakang: Adiponektin, hormon yang disekresikan oleh adiposit yang berperan pada homeostasis energi 
dan memiliki efek antiinflamasi, antioksidan, endothelium serta efek protektif terhadap endotelium dan miokard 
dengan fungsi regulasi yang positif terhadap mikrosirkulasi koroner. Meskipun secara fisiologis peran adiponektin 
masih belum diketahui secara pasti,namun adiponektin berperan pada proses inflamasi atau metabolisme lipid, 
yang berkontribusi terhadapa proses aterosklerosis. Pada studi ini, kami melakukan evaluasi kadar konsentrasi 
adiponektin pada pasien CAD, aliran darah lambat dan subjek sehat. Metode: penelitian ini dilakukan dengan 
design cross-sectional yang melibatkan 30 pasien CAD, 30 pasien SCF dan 30 pasien subjek sehat dari Desember 
2017-Februari 2018 di RSUD dr. Zainoel Abidin, Banda Aceh, Indonesia. Kadar plasma adiponektin di ukur 
dengan menggunakan alat immunosorbent enzyme-linked (ELISA) sesuai dengan spesifikasi alat. Hasil: terdapat 
hasil yang signifikan bermakna secara statistik di antara subjek CAD, SCF dan subjek sehat dalam hal usia, 
jenis kelamin, tekanan darah sistolik, kolesterol total, trigliserida dan kreatinin dengan p<0,001. Rerata kadar 
konsentrasi adiponektin pada pasien CAD secara signifikan menunjukkan nilainy yang lebih rendah dibandingkan 
pasien dengan SCF dan subjek sehat (CAD 3,40 (0,87) μg/ml; SCF 4,58 (2,32) μg/ml; subyek sehat 5,65 (4,87) 
μg/ml; P<0,001). Kesimpulan: penelitian ini menunjukkan kadar plasma adiponektin yang rendah merupakan 
molekul penting yang berhubungan dengan aterosklerosis. Kadar plasma adiponektin mungkin berhubungan 
dengan peran terjadinya patofisiologi dari penyakit kardiovaskular baik pasien CAD dan CSF.
Kata kunci: Adiponektin, penyakit arteri koroner, Aliran darah lambat.
ABSTRACT
Background: Adiponectin, an adipocyte-secreted hormone involved in energy homeostasis, has broad 
anti-inflammatory, antioxidant, and endothelium- and myocardial-protective effects, together with a potentially 
positive regulatory function in coronary microcirculation. Although the physiological role of adiponectin has 
not yet been fully elucidated, it may well be involved in the regulation of many of the inflammatory processes 
or lipid metabolisms that contribute to atherosclerosis. In this study we investigate the plasma concentration 
of adiponectin in patients with coronary artery disease (CAD), those with coronary slow flow (CSF) and in 
healthy subjects. Methods: this study was conducted according to a cross-sectional design involving 30 CAD, 30 
CSF, and 30 healthy subjects. These subjects were sourced from the Dr. Zainoel Abidin Center Hospital, Banda 
Aceh, Indonesia, between December 2017 and February 2018. The plasma concentration of adiponectin was 
measured using enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s specifications. 
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Results: there were statistically significant differences at p<0.001 between the CAD, CSF, and healthy-subject 
groups in terms of age, sex, systolic blood pressure, total cholesterol, triglycerides, and creatinine. Mean plasma 
concentrations of adiponectin in patients with CAD were significantly lower than in patients with CSF and in 
healthy subjects (CAD: 3.40 (0.87) μg/ml; CSF: 4.58 (2.32) μg/ml; healthy subjects: 5.65 (4.87) μg/ml; P<0.001). 
Conclusion: the findings suggest that low plasma adiponectin concentration is associated with atherosclerosis. 
Plasma concentrations of adiponectin may be related to the pathophysiology role of cardiovascular disease in 
both CAD and CSF patients.
Keywords: Adiponectin, coronary artery disease, coronary slow flow.
INTRODUCTION
Adiponectin is one of the most intensively 
discussed secretion products of white fat cells, 
having been increasingly implicated in the 
pathogenesis of atherosclerosis and insulin 
resistance.1 A previous study detected adiponectin 
in catheter-injured vascular walls of rats but not 
in intact vascular walls. Separate studies have 
shown that plasma adiponectin accumulates in 
the subendothelial space of the vascular wall at 
an early phase of catheter injury and that it can 
be detected around macrophages in the injured 
human aorta at the site of a thrombus.2,3
Data on the prospective impact of 
adiponectin plasma-concentration determination 
in cardiovascular disease in humans are evolving. 
Several clinical studies have demonstrated 
a strong association between low plasma 
adiponectin levels and coronary artery disease 
(CAD). In addition, decreased adiponectin 
concentrations have been shown to be implicated 
in the pathogenesis of cardiovascular risk as 
being related to endothelial dysfunction. Despite 
these advances in understanding, the exact 
relationship between plasma concentrations of 
adiponectin and CAD remains unclear in clinical 
practice.4 In this study, we focus particularly 
on the plasma concentration of adiponectin in 
patients with CAD, CSF, and in healthy subjects.
METHODS
This cross-sectional study was conducted 
between December 2017 and February 2018 in 
the Division of Cardiology, Internal Medicine 
Department, Faculty of Medicine, University 
of Syiah Kuala, Banda Aceh and the Cardiac 
Catheterization Laboratory, Dr. Zainoel Abidin 
Hospital, Banda Aceh. Patients aged >26 years 
were consecutively recruited into one of three 
groups: CAD, CSF, and healthy subjects. All 
study participants had been referred for coronary 
angiography because of exertional chest pain 
suggestive of stable angina pectoris. Exclusion 
criteria were the presence of total stenosis of 
coronary arteries, patients who had undergone 
coronary artery bypass graft, and healthy 
subjects with significant comorbidity, including 
hypertension, diabetes mellitus, the use of anti-
inflammatory drugs other than aspirin, renal 
and/or hepatic dysfunction, BMI >22.9 kg/m2 or 
<18.5 kg/m2, smoking, and alcohol consumption.
The study has been approved by the Ethical 
Review Committee of the Medical Faculty of 
Universitas Sumatera Utara, Medan, Indonesia; 
reference number 476/TGL/KEPK FK USU-
RSUP HAM/2017 on September 14, 2017 and all 
subjects provided informed consent for the study. 
Laboratory Measurement
Venous blood was drawn from all subjects 
after an overnight fast. Routine hematology, 
total cholesterol, high-density lipoprotein 
(HDL) cholesterol, triglycerides, glucose, urea, 
and creatinine levels were measured using 
conventional methods. The concentration of 
adiponectin (μg/ml) was measured using enzyme-
linked immunosorbent assay (ELISA) according 
to the manufacturer’s specifications (R&D 
Systems).
Coronary Angiography
Coronary angiography was performed using 
the standard Judkins technique. A contrast 
agent was injected manually during coronary 
angiography (6–10 ml of contrast agent at each 
position using right and left, and cranial and caudal 
angulations). Coronary angiography recordings 
were taken at the left anterior oblique, cranial and 
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right anterior oblique, and caudal and horizontal 
positions. All angiographic examinations were 
conducted by two cardiologists who were blind 
to the clinical characteristics of the patients. They 
assessed the flow in coronary arteries using the 
thrombolysis in myocardial infarction (TIMI) 
frame-count method described by Gibson et al.5
TIMI frame count was calculated from the 
difference between the first and last frames. 
Since the distance between proximal and distal 
bifurcation in the left anterior descending (LAD) 
coronary artery is longer than in other coronary 
arteries, LAD TIMI frame count is significantly 
higher than those of the right coronary artery 
(RCA) and the circumflex (Cx) artery. The 
cutoff values in respect of length for normal 
visualization of coronary arteries were 36.2 (SD 
2.6) frames for the LAD, 22.2 (SD 4.1) frames 
for the left Cx (LCx), and 20.4 (SD 3) frames 
for the RCA. The corrected cutoff value for the 
LAD coronary artery was 21.1 (SD 1.5) frames. 
All participants with a corrected TIMI frame 
count greater than the two standard deviations 
of the published range for the particular vessel 
were considered as having CSF. The mean TIMI 
frame count for each patient and control subject 
was calculated by dividing the sum of the TIMI 
frame count for LAD, LCx, and RCA by 3.
Statistical Analysis
Continuous variables are presented as mean 
(standard deviation) and categorical variables 
are presented as n (%) prevalence. Conformity 
to normal distribution of the continuous variables 
was examined using the Shapiro–Wilk test. 
According to data distribution and number 
of groups, a parametric (analysis of variance 
[ANOVA], t test) or nonparametric (Kruskal–
Wallis, Mann–Whitney) test was then performed. 
Post hoc comparisons were performed with 
the appropriate test for data distribution. The 
Pearson’s or Spearman correlation test was 
used for evaluation of the correlation between 
variables. A value of P<0.05 was considered 
statistically significant.
Table 1. Demographic and clinical characteristics of the subjects in the three groups
Variables CAD (n = 30) CSF (n = 30) Healthy subjects (n = 30)
Age (years), median (range) 55 (37–65) 52 (37–65) 35 ( 27–51)
Sex-male, n (%) 29 (96.0) 10 (33.0) 17 (56.0)
BMI (kg/m2), median (range) 23.7 (21.6–29.0) 22.7 (18.1–31.2) 23.2 (18.5–25.1)
SBP (mmHg), median (range) 130 (112–152) 126.50 (109–147) 116.50 (107–128)
DBP (mmHg), mean (SD) 84.30 (7.13) 84.93 (9.63) 78.10 (8.84)
Hemoglobin (g/dl), median (range) 14.2 (10.1–17.1) 13.2 (8.7–16.6) 13.2 (11.6–17.5)
Hematocrit (%), mean (SD) 42.17 (4.93) 39.90 (4.85) 39.93 (3.44)
WBC (ul), median (range) 8350 (5900–14,900) 8700 (4600–16,600) 7700 (4500–10,100)
Platelets (103/ul), mean (SD) 263.4 (59.4) 270.7 (74.2) 278.1 (65.2)
Neutrophil-lymphocyte count ratio,  
median (range) 1.6 (0.8–19) 1.3 (0.8–5.1) 1.3 (0.8–1.7)
Total cholesterol (mg/dl), median (range) 198 (112–461) 194 (127–336) 149 (90–198)
LDL cholesterol (mg/dl), mean (SD) 50.4 (18.31) 49 (17.7) 64.8 (14.5)
HDL cholesterol (mg/dl), median (range) 121.5 (30–225) 129 (50–252) 111 (62–156)
Triglyceride (mg/dl), median (range) 143.5 (88–231) 106 (55–373) 94 (21–129)
Urea (mg/dl), mean (SD) 30.9 (11.03) 23.8 (6.62) 23.3 (5.20)
Creatinin (mg/dl), median (range) 1.0 (0.6–1.6) 0.8 (0.6–1.3) 0.7 (0.5–1.0)
Fasting glucose (mg/dl), median (range) 101 (71–218) 109 (89–154) 98 (82–117)
2 hours post-prandial glucose (mg/dl), 
median (range) 129 (100–226) 133 (103–226) 126 (97–176)
Data presented as mean (SD) or n (%) prevalence. Nonparametric tests were used and the medians of these data are 
presented: body mass index (BMI); systolic blood pressure (SBP); diastolic blood pressure (DBP); white blood count (WBC); 
low-density lipoprotein (LDL); high-density lipoprotein (HDL).
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Table 2. Baseline characteristics of TIMI frame counts for angiographic data of patients with CAD and CSF
TIMI frame CAD (n = 30) CSF (n = 30) P value
RCA (frame), mean (SD) 28.07 (8.82) 26.83 (3.87) 0.486
LCX (frame), mean (SD) 34.4 (10.34) 28.37 (2.76) 0.003
LAD (frame), mean (SD) 47.27 (10.11) 42.37 (7.77) 0.04
cTFC LAD (frame), mean (SD) 27.8 (5.9) 24.67 (4.8) 0.029
cTFC (frame), mean (SD) 30.13 (7.94) 26.83 (3.553) 0.042
Target vessel, n (%)
 - RCA 22 (73.3) 28 (93.3) 0.038
 - LCx 4 (66.6) 25 (83.3) 0.136
 - LAD 26 (86.6) 25 (83.3) 0.718
Right coronary artery (RCA); left circumflex artery (LCx); left anterior descending artery (LAD); corrected 
thrombolysis in myocardial infarction (cTFC).
Table 3. Between-group comparison of adiponectin level in CAD, CSF, and healthy subjects
Mean (SD) Median (min-max) 95% confidence interval P value
CAD (n = 30) 3.40 (0.87) 3.35 (1.48–4.95) 2.99–3.81 < 0.001
CSF (n = 30) 4.58 (2.32) 4.15 (1.63–9.99) 3.50–5.67
Healthy subjects (30) 5.65 (4.87) 4.87 (3.27–9.45) 4.80–6.50
Kruskal–Wallis analysis, A post hoc Mann–Whitney test showed healthy vs. CSF p = 0.045; healthy vs. CAD p<0.001; and 
CAD vs. CSF p = 0.157
RESULTS
The study included 90 subjects: 30 patients 
with CAD (the CAD group); 30 patients with 
only coronary slow flow (the CSF group) and 
30 healthy subjects. Demographic and clinical 
characteristics of the patients are summarized 
in Table 1.
Based on the clinical data, there was a 
statistically significant difference (at p<0.001) 
between the CAD, CSF, and healthy-subject 
groups in terms of age, sex, and SBP. Using 
another correlation analysis, total cholesterol, 
serum triglycerides, and creatinine were also 
significantly higher in subjects with CAD 
compared to both subjects with CSF and healthy 
subjects (p<0.001).
The baseline characteristics of the TIMI 
frame counts for CAD, CSF, and healthy 
subjects are shown in Table 2. The corrected 
TIMI frame counts for RCA and mean corrected 
thrombolysis in myocardial infarction (cTFC) 
were significantly higher in patients with CSF 
than in those with CAD (123.10 (SD 27.89) vs. 
105.85 (SD 20.27), P = 0.034; 91.85 (SD 12.56) 
vs. 83.75 (SD 13.64), P=0.006, respectively) 
and the most common target vessel in the CSF 
group was RCA (93.3%, P = 0.038) for all three 
coronary arteries.
Mean plasma adiponectin concentrations 
were found to be significantly lower in the CAD 
and CSF subjects than in the healthy subjects 
(3.40 (0.87) μg/ml; 4.58 (2.32) μg/ml; and 5.65 
(4.87) μg/ml, respectively; P<0.001)
DISCUSSION
The objective of the study was to investigate 
whether the plasma levels of adiponectin differed 
between subjects. The study demonstrated 
that the plasma levels of adiponectin differed 
significantly between groups of patients with 
CAD, CSF, and healthy subjects.
CAD, also known as ischemic heart disease 
or coronary heart disease, has become one 
of the major causes of death worldwide. 
Atherosclerosis, which is the main cause of 
CAD, is an inflammatory process involving the 
vascular wall cells and activation of markers of 
inflammation such as monocytes, T lymphocytes, 
pro-inflammatory cytokines, chemoattractant 
cytokines (chemokines), and growth factors.6 
Vessel-wall inflammation is a central feature in 
the initiation, progression, and terminal stages 
of atherosclerosis, leading to plaque, rupture, 
and thrombosis, and many systemic markers of 
Muhammad Diah                                                                                                                  Acta Med Indones-Indones J Intern Med
294
inflammation have been investigated and linked 
to the prediction of future cardiovascular events 
and to identification of patients at risk.7,8
During the last decade, much interest has 
been focused on adiponectin as an important 
modulator of inflammatory response during the 
initiation and progression of atherosclerosis in 
the vascular wall.9 Adiponectin is a collagen-like 
protein produced specifically by adipose tissue 
that is abundantly present in the circulation. A 
recent report concluded that plasma adiponectin 
concentrations were related to the severity 
of coronary atherosclerosis, although the 
difference fell short of significance, in that 
adiponectin concentrations decreased as the 
number of significantly narrowed coronary 
arteries increased.10 In vitro and in vivo studies 
have reported that circulating adiponectin shows 
multiple protective effects on the vascular 
endothelium by inhibiting various crucial steps 
in the atherosclerotic process. Adiponectin has 
been shown to attenuate monocyte attachment to 
endothelial cells by reducing adhesion-molecule 
expression, suppressing macrophage-to-foam 
cell transformation, and decreasing proliferation 
and migration of vascular smooth-muscle 
cells.11-13 In our study, we found significantly 
differences in the levels of plasma serum 
adiponectin between the three groups, with the 
level being lowest in the CAD group. However, 
plasma concentration of adiponectin has been 
differently reported by Lim et al.14, whose study 
showed that adiponectin concentrations did not 
correlate with coronary atheroma or coronary 
stenosis scores.
In the literature, there are a number of 
clinical reports identifying the crucial role of 
endothelial dysfunction in the pathogenesis 
of CSF. Selcuk et al.9 showed that plasma 
adiponectin concentrations were significantly 
decreased in patients with CSF compared to 
those with normal coronary flow. It has been 
suggested that loss of the anti-inflammatory 
effects of adiponectin and increased endothelial 
expression of proinflammatory factors directly 
contribute to endothelial dysfunction by allowing 
vascular proinflammatory reactions to occur 
more readily.15 In this mechanism, decreased 
concentrations of circulating adiponectin may 
be attributed to impaired endothelial function 
resulting from slow-flow-induced vascular 
damage that gives rise to the accumulation of 
adipocytokine in the vessel wall.16 Our study 
showed that plasma concentration of adiponectin 
was lower in patients with CSF than in healthy 
subjects.
Our study had some limitations. First, the 
number of participants was relatively low. 
Second, the patients did not undergo intravascular 
ultrasonography (IVUS) to detect atherosclerotic 
Figure 1. Comparison of plasma concentrations of adiponectin in patients with 
CAD, CSF and healthy subjects
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changes in the coronary arteries. Finally, we 
did not measure the inflammatory indicators 
as supporting evidence for the mechanisms of 
pathophysiology in cardiovascular disease.
CONCLUSION
The results of this study show that plasma 
adiponectin is an important molecule associated 
with atherosclerosis, and, for the data obtained, the 
level of adiponectin is lowest in the CAD group. 
These findings may have important implications 
for understanding the physiopathologic role of 
cardiovascular disease in both CAD and CSF 
patients and therefore for the development of 
therapeutic strategies.
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